DSX Therapeutics
DSX Therapeutics aims to develop and commercialize innovative diagnostics and therapeutics for sepsis and other inflammatory disorders. Their mission is to provide effective treatments and early diagnostic tools to improve patient outcomes and address unmet medical needs in sepsis care.
Industries
Nr. of Employees
small (1-50)
DSX Therapeutics
9030 West Sahara Avenue #403, Las Vegas, NV 89117, USA
Products
Plasma iNOS in vitro diagnostic (IVD) test
An immunoassay–based diagnostic test detecting inducible nitric oxide synthase (iNOS) in plasma to identify early-stage sepsis and predict organ dysfunction.
Monoclonal antibody therapy targeting microvesicle-associated iNOS
A chimeric monoclonal antibody developed to bind and neutralize microvesicle-associated iNOS circulating in blood; demonstrated in preclinical studies to neutralize deleterious effects in vivo.
Plasma iNOS in vitro diagnostic (IVD) test
An immunoassay–based diagnostic test detecting inducible nitric oxide synthase (iNOS) in plasma to identify early-stage sepsis and predict organ dysfunction.
Monoclonal antibody therapy targeting microvesicle-associated iNOS
A chimeric monoclonal antibody developed to bind and neutralize microvesicle-associated iNOS circulating in blood; demonstrated in preclinical studies to neutralize deleterious effects in vivo.
Services
Partnership engagement for further clinical development, commercialization, and translation of diagnostic and therapeutic programs targeting inflammatory pathologies.
Partnership engagement for further clinical development, commercialization, and translation of diagnostic and therapeutic programs targeting inflammatory pathologies.
Expertise Areas
- Sepsis diagnostics development
- Monoclonal antibody therapeutic development
- Biomarker discovery and validation
- Clinical trial execution and analysis
Key Technologies
- Monoclonal antibody–based immunoassays
- Biomarker detection in plasma (iNOS)
- Microvesicle isolation from blood
- Flow cytometry–based clinical assays
News & Updates
The patent EP1773390B1 titled 'Improved Therapeutic Agent for iNOS Generating Illness' was published in May 2015.
In October 2014, DSX Therapeutics received approval from the European Patent Office for their patent application.
Development of cell culture based efficacy assay for aSeptiMab™
In May 2013, DSX developed an efficacy assay for their candidate therapy aSeptiMab™.
Filed PCT patent application with WIPO for Panel of Sepsis Biomarkers
In September 2012, DSX filed a patent application for a panel of sepsis biomarkers.
Dr. Webber named 'Researcher of the Year' by NevBio
In September 2012, Dr. Robert Webber was recognized as Researcher of the Year.
European Patent Office published a decision to grant patent EP1773390B1 for DSX's therapeutic agent for iNOS illnesses.
The patent EP1773390B1 titled 'Improved Therapeutic Agent for iNOS Generating Illness' was published in May 2015.
In October 2014, DSX Therapeutics received approval from the European Patent Office for their patent application.
Development of cell culture based efficacy assay for aSeptiMab™
In May 2013, DSX developed an efficacy assay for their candidate therapy aSeptiMab™.
Filed PCT patent application with WIPO for Panel of Sepsis Biomarkers
In September 2012, DSX filed a patent application for a panel of sepsis biomarkers.
Dr. Webber named 'Researcher of the Year' by NevBio
In September 2012, Dr. Robert Webber was recognized as Researcher of the Year.
European Patent Office published a decision to grant patent EP1773390B1 for DSX's therapeutic agent for iNOS illnesses.